Loading organizations...

§ Private Profile · 100 Forge Road Suite 400, Watertown, MA 02472, USA
Remix Therapeutics is a technology company.
Remix Therapeutics is a clinical-stage biotechnology company developing small molecule therapies that modulate RNA processing to address disease drivers. Leveraging its proprietary REMaster™ platform, the company designs compounds to control RNA expression. Their lead candidate, REM-422, is an orally available small molecule mRNA degrader targeting MYB, a transcription factor implicated in diverse diseases.
Remix Therapeutics was co-founded in 2020 by Peter Smith, PhD, who leads the company as President and Chief Executive Officer. The company originated from the insight that precisely modulating RNA processing with small molecules provides a powerful new approach to impact disease-driving gene expression. Dr. Smith’s prior extensive drug discovery leadership in oncology underpins this innovative scientific foundation.
Remix aims to bring novel therapeutic options to patients suffering from diseases with high unmet medical needs, exemplified by those with MYB-driven cancers targeted by REM-422. The company's vision is to transform patient outcomes by systematically addressing previously undruggable targets through its RNA-centric approach, rapidly advancing its drug discovery programs into clinical development.
Remix Therapeutics has raised $271.0M across 5 funding rounds.
Remix Therapeutics has raised $271.0M in total across 5 funding rounds.
Remix Therapeutics is a clinical-stage biotechnology company developing small‑molecule therapies that modulate RNA processing to change how disease‑driving genes are expressed, using a proprietary REMaster drug‑discovery platform to identify orally available modulators and mRNA degraders for diseases with high unmet medical need.[1][2]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech and Biotech Landscape
Quick Take & Future Outlook
Quick factual notes: Remix is a private, clinical‑stage biotech founded circa 2018 with headquarters in the Cambridge/Watertown, MA area and public disclosures of key collaborations and programs available on its website and press releases.[4][1][2]
Remix Therapeutics has raised $271.0M in total across 5 funding rounds.
Remix Therapeutics's investors include Peter Svennilson, Alexandria Venture Investments, ARCH Venture Partners, Atlas Venture, Casdin Capital, Foresite Capital, Surveyor Capital, Willett Advisors, WTT Investment, The Column Group, Access Biotechnology, Bison Ventures.
Remix Therapeutics has raised $271.0M across 5 funding rounds. Most recently, it raised $60.0M Other Equity in January 2024.